Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
  • A61K39/095—Neisseria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
  • A61K2039/541—Mucosal route

Definitions

• the present invention relates to Neisseria ORF2086 proteins (Subfamily A and Subfamily B), which may be isolated from bacterial strains such as those of Neisseria species, including strains of Neisseria meningitidis (serogroups A, B, C, D, W-135, X, Y 1 Z and 29E ), Neisseria gonorrhoeae, and Neisseria lactamica, as well as immunogenic portions and/or biological equivalents of said proteins.
• the present invention also relates to antibodies that immunospecifically bind to said proteins, immunogenic portions and/or biological equivalents.
• the present invention relates to isolated polynucleotides comprising nucleic acid sequences encoding any of the foregoing proteins, immunogenic portions, biological equivalents and/or antibodies. Additionally, the present invention relates to immunogenic compositions and their use in preventing, treating and/or diagnosing meningococcal infection caused by N. meningitidis, and in particular meningococcal disease caused by N. meningitidis serogroup B, as well as methods for preparing said compositions. This invention relates to both recombinant forms and forms isolated from a natural source, as well as both lipidated and non-lipidated forms.
• Meningococcal meningitis is a devastating disease that can kill children and young adults within hours despite the availability of antibiotics. Pizza et a/., 2000, Science 287:1816-1820. Meningitis is characterized as an inflammation of the meninges resulting in an intense headache, fever, loss of appetite, intolerance to light and sound, rigidity of muscles, especially in the neck, and in severe cases convulsions, vomiting and delirium leading to death. The symptoms of meningococcal meningitis appear suddenly and culminate in meningococcal septicemia with its characteristic hemorrhagic rash. A rapid diagnosis and immediate treatment with large doses of antibiotics is critical if there is to be any chance of survival. 2000. Bantam Medical Dictionary, Third Edition 302.
• Meningococcal meningitis is caused by Neisseria meningitidis (the meningococcus), a Gram-negative, capsulated bacterium that has been classified into several pathogenic serogroups including A, B, C, D 1 W-135, X, Y, Z and 29E.
• Serogroup B strains of N. meningitidis are a major cause of meningococcal disease throughout the world. For example, it is reported in the medical literature that serogroup B is responsible for about 50% of bacterial meningitis in infants and children residing in the United States and Europe. No vaccine currently exists to prevent meningococcal disease caused by N. meningitidis serogroup B.
• Vaccines based on polysaccharide conjugates have been developed against N. meningitidis serogroups A and C and appear to be effective in preventing disease.
• an immunogenic composition made of capsular polysaccharide from serogroups A, C, Y, & W-135 is available. Ambrosch et al., 1983, lmmunogenicity and side-effects of a new tetravalent. Bulletin of the World Health Organization 61 (2):317-23.
• this immunogenic composition elicits a T-cell independent immune response, is not effective in young children, and provides no coverage for serogroup B strains, which cause upwards of 50% of meningococcal disease.
• PorA proteins thus serve as the serosubtyping antigens (Abdillahi et al., 1988, Microbial Pathogenesis 4(1):27-32) for meningococcal strains and are being actively investigated as components of a serogroup B immunogenic composition (Poolman, 1996, Adv. Exp. Med. Biol. 397:73-7), since they can elicit bactericidal antibodies (Saukkonen, 1987, Microbial Pathogenesis 3(4):261-7). Bactericidal antibodies are thought to be an indicator of protection and any new immunogenic composition candidate should elicit these functional antibodies.
• An embodiment of the present invention provides a polynucleotide comprising: (a) a nucleotide sequence having at least about 95% sequence identity to any of the odd numbered sequences of SEQ ID NOS:1-11 ; or (b) a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence having at least about 95% sequence identity to an amino acid sequence of any of the even numbered sequences of SEQ ID NOS:2-12.
• a further embodiment of the present invention provides a vector comprising a polynucleotide of the present invention.
• An even further embodiment of the present invention provides a recombinant cell comprising a vector of the present invention.
• a still further embodiment of the present invention provides a polypeptide comprising: (a) an amino acid sequence having at least 95% sequence identity to any of the even numbered sequences of SEQ ID NOS:2-12; (b) an amino acid sequence that is encoded by a nucleotide sequence having at least 95% sequence identity to any of the odd numbered sequences of SEQ ID NOS:1-11 ; (c) at least one immunogenic portion of an amino acid sequence described in (a) or (b); or (d) at least one biological equivalent of an amino acid sequence described in (a) or (b) or immunogenic portion described in (c).
• a still further embodiment of the present invention provides an antibody comprising any of: (a) a polypeptide that immunospecifically binds with a polypeptide comprising an amino acid sequence of any of even numbered SEQ ID NOS:2-12; or (b) at least one immunogenic portion of the polypepetide described in (a); or (c) at least one biological equivalent of the polypeptide described in (a) or immunogenic fragment described in (b).
• a still further embodiment of the present invention provides a composition comprising a polynucleotide, vector, recombinant cell, polypeptide or antibody of the present invention.
• a still further embodiment of the present invention provides a composition comprising: (a) a first polynucleotide comprising a nucleotide sequence having at least about 95% sequence identity to any of the odd numbered sequences of SEQ ID NOS: 1-5 or at least about 95% sequence identity to a nucleotide sequence that encodes an amino acid sequence of any of the even numbered sequences of SEQ ID NOS:2-6; and (b) a second polynucleotide comprising a nucleotide sequence having at least about 95% sequence identity to of any of the odd numbered sequences of SEQ ID NOS:7-11 or at least about 95% sequence identity to a nucleotide sequence that encodes the amino acid sequence of any of the even numbered sequences of SEQ ID NOS:8-12.
• a still further embodiment of the present invention provides a composition comprising: (a) a first polypeptide comprising an amino acid sequence having at least about 95% sequence identity to any of the even numbered sequences of SEQ ID NOS:2-6; and (b) a second polypeptide comprising an amino acid sequence having at least about 95% sequence identity to any of the even numbered sequences of SEQ ID NOS:8-12.
• a still further embodiment of the present invention provides a composition prepared by a process comprising: isolating and purifying from Neisseria species or recombinantly preparing any of: (a) a polypetide comprising the amino acid sequence of any of even numbered SEQ ID NOS:2-12; (b) a polypeptide encoded by a polynucleotide comprising the nucleic acid sequence of any of odd numbered SEQ ID NOS: 1-11 ; (c) at least one immunogenic portion of the polypeptide described in (a) or (b); or (d) at least one biological equivalent of the polypeptide described in (a) or (b) or immunogenic fragment described in (c).
• a still further embodiment of the present invention provides the use of a composition of the present invention in the preparation of a medicament for inducing an immune response in a mammal.
• a still further embodiment of the present invention provides the use of a composition of the present invention in a medicament effective against bacterial meningitis in a mammal.
• a still further embodiment of the present invention provides a method of preparing a composition comprising expressing in a host cell a nucleic acid sequence encoding any of the polypeptides described herein.
• a still further embodiment of the present invention provides a method of preparing an antibody composition comprising recovering antibodies from an animal after introducing into the animal a composition comprising any of the proteins, immunogenic portions or biological equivalents described herein.
• a still further embodiment of the present invention provides a method of inducing an immune response in a mammal comprising administering to the mammal an effective amount of one or more of the compositions of the present invention.
• a still further embodiment of the present invention provides a method of preventing or treating bacterial meningitis in a mammal comprising administering to the mammal an effective amount of one or more of the compositions of the present invention.
• FIG. 1A depicts an SDS-PAGE gel that depicts the two major proteins of the protein fractions obtained from the experiments for identifying neisserial membrane protein extract that is capable of eliciting bactericidal antibodies against heterologous strains.
• FIG. 1 B depicts the results from the experiments from the identification of the two major proteins by analysis of TMAE Flow Through components by protease digestion and reverse Phase N-terminal sequencing.
• FIG. 2 depicts the purification scheme and homogeneity as determined by SDS- PAGE of rl_P2086.
• FIG. 3 depicts the results from the experiments from the identification of the two major proteins and one minor protein by analysis of TMAE Flow Through components by LC-MS/MS and the corresponding SDS-PAGE.
• FIG. 4 is an SDS-PAGE gel from the recombinant expression of 2086 protein.
• FIG. 5 is a schematic diagram of plasmid pPX7340, as described in the examples herein.
• FIG. 6 is a schematic diagram of plasmid pPX7328 as described in the examples herein.
• FIG. 7 is a schematic diagram of plasmid pPX7343 as described in the examples herein.
• FIG. 8 illustrates N-terminal regions of 2086 gene from various strains.
• FIG. 9A is a flow chart showing the preliminary steps in the identification of an immunogenic component in a neisserial strain.
• FIG. 9B is a flow chart showing the final steps in the identification of an immunogenic component in a neisserial strain.
• FIG. 10A is a schematic diagram of the pBAD arabinose inducible promoter which drives the expression of the P4 signal/ORF2086 fusion protein to express a lipidated form of rP2086 as described in the examples herein.
• FIG. 10B is a schematic diagram of the pET9a-T7 vector for recombinant expression of nonlipidated form of ORF2086.
• FIG. 1 1A is a photograph representing whole cell lysates of E. coli B expressing the rl_P2086 protein.
• FIG. 11 B shows whole cell lysates of E. coli B expressing the rP2086 protein.
• FIG. 12 is a phylogenetic tree showing an organization of the subfamilies and groups of ORF2086 proteins according an implementation of the present invention.
• FIG. 13 is a graphic illustration of whole cell ELISA data for the rl_P2086 Subfamily A antisera.
• FIG. 14 is a graphical illustration of whole cell ELISA data for the rLP2086 Subfamily B antisera.
• FIG. 15 is a graphical illustration of the results of the rLP2086 mixing study - WCE Titers.
• FIG. 16 is a graphical illustration of the results of the rLP2086/rPorA mixing study - WCE Titers.
• FIG. 17 is a Western Blot showing reactivity of rl_P2086 mouse antisera to P2086 Subfamily B N. meningitidis whole cell lysates.
• FIG. 18 is a Western Blot showing reactivity of rLP2086 mouse antisera to P2086 Subfamily A N. meningitidis and N. lactamica whole cell lysates.
• SEQ ID NO:1 nucleic acid sequence encoding amino acid sequence for mature 2086 protein from CDC1135 strain when combined with a native leader sequence.
• SEQ ID NO:2 amino acid sequence for mature 2086 protein from CDC1135 strain prepared using a native leader sequence.
• SEQ ID NO:3 nucleic acid sequence for encoding amino acid sequence for mature 2086 protein from CDC1135 when combined with a P4 leader sequence.
• SEQ ID NO:4 amino acid sequence for mature 2086 protein from CDC1135 strain prepared using a P4 leader sequence.
• SEQ ID NO:5 nucleic acid sequence encoding amino acid sequence for mature 2086 protein from CDC1135 strain.
• SEQ ID NO:6 amino acid sequence for mature 2086 protein from CDC1135 strain.
• SEQ ID NO:7 nucleic acid sequence encoding amino acid sequence for mature 2086 protein from CDC1127 strain when combined with a native leader sequence.
• SEQ ID NO:8 amino acid sequence for mature 2086 protein from CDC1127 strain prepared using a native leader sequence.
• SEQ ID NO:9 nucleic acid sequence for encoding amino acid sequence for mature 2086 protein from CDC1127 when combined with a P4 leader sequence.
• SEQ ID NO:10 amino acid sequence for mature 2086 protein from CDC1127 strain prepared using a P4 leader sequence.
• SEQ ID NO:11 nucleic acid sequence encoding amino acid sequence for mature 2086 protein from CDC1127 strain.
• the present invention provides Neisseria ORF2086 proteins ("2086 proteins"), including 2086 Subfamily A proteins and 2086 Subfamily B proteins.
• 2086 proteins are proteins that can be isolated from native neisserial strains, including strains of Neisseria meningitidis (serogroups A, B, C, D 1 W-135, X, Y, Z and 29E ), Neisseria gonorrhoeae, and Neisseria lactamica.
• the 2086 proteins may also be prepared using recombinant technology.
• the present invention provides the 2086 proteins, immunogenic portions thereof, and/or biological equivalents thereof, antibodies that immunospecifically bind to any of the foregoing, and polynucleotides comprising nucleic acid sequences that encode any of the foregoing.
• the present invention includes compositions, immunogenic compositions and their use in preventing, treating and/or diagnosing meningococcal infection, and in particular meningococcal disease caused by N. meningitidis, as well as methods for preparing said compositions.
• the 2086 proteins herein include recombinant forms and forms isolated from a natural source, as well as both lipidated and non-lipidated forms.
• the present invention unexpectedly and advantageously provides compositions that (1) elicit bactericidal antibodies to multiple neisserial strains, such as strains of N. meningitidis, N. gonorrhoeae, and/or N. lactamica; (2) react with the surface of multiple strains; (3) confer passive protection against a live challenge; and/or (4) prevent colonization, as well as methods of using said compositions and methods of preparing said compositions.
• neisserial strains such as strains of N. meningitidis, N. gonorrhoeae, and/or N. lactamica
• ORF2086 protein also referred to as "2086 protein” or "ORF2086” protein, used interchangeably herein, or P2086 for the non-lipated proteins and LP2086 for the lipidated version of the proteins isolated from N. meningitidis were identified by combining cell fractionation, differential detergent extraction, protein purification, with the preparation of antisera, and a bactericidal activity assay utilizing multiple strains.
• this invention relates to compositions and methods of treating and/or preventing meningococcal infection through the use of proteins, immunogenic portions thereof and biological equivalents thereof, as well as genes encoding said polypeptides, portions and equivalents, and antibodies that immunospecifically bind to same.
• non-strain specific refers to the characteristic of an antigen to elicit an immune response effective against more than one strain of ⁇ /. meningitidis (e.g., heterologous meningococcal strains).
• cross-reactive as it is used herein is used interchangeably with the term “non-strain specific”.
• immunogenic non-strain specific N. meningitidis antigen describes an antigen that can be isolated from N. meningitidis, although it can also be isolated from another bacterium (e.g., other neisserial strains, such as gonococcal strains, for example), or prepared using recombinant technology.
• the 2086 proteins of the present invention include lipidated and non-lipidated proteins. Further, the present invention also contemplates the use of the immature proteins or preproteins that correspond to each protein as intermediate compounds/compositions.
• the present invention also provides antibodies that immunospecifically bind to the foregoing immunogenic agents, according to implementations of the invention. Further, the present invention relates to isolated polynucleotides comprising nucleic acid sequences encoding any of the foregoing. Additionally, the present invention provides compositions and/or immunogenic compositions and their use in preventing, treating and/or diagnosing meningococcal meningitis, in particular serogroup B meningococcal disease, as well as methods for preparing said compositions.
• compositions of the present invention are highly immunogenic and capable of eliciting the production of bactericidal antibodies. These antibodies are cross-reactive to serogroup, serotype and serosubtype heterologous meningococcal strains. Accordingly, the present compositions overcome the deficiencies of previous N. meningitidis vaccine attempts by exhibiting the ability to elicit bactericidal antibodies to heterologous neisserial strains. Thus, among other advantages, the present invention provides immunogenic compositions that can be compounded with fewer components to elicit protection comparable to previously used agents.
• compositions or immunogenic agents therein can be used alone or in combination with other antigens or agents to elicit immunological protection from meningococcal infection and disease, as well as to elicit immunological protection from infection and/or disease caused by other pathogens.
• purified 2086 protein will dramatically and unexpectedly reduce the number of proteins required to provide adequate immunogenic coverage of the strains responsible for meningococcal disease.
• the 2086 protein can be recombinantly expressed in E. coli as a lipoprotein, which is the wild type form of the protein, at levels much higher than in the native meningococci.
• the 2086 protein is not present in large amounts in wild type strains, it is a target for bactericidal antibodies. These antibodies, unlike those produced in response to the PorAs, are capable of killing strains expressing heterologous serosubtypes.
• Antibodies to the 2086 protein also passively protect infant rats from challenge with meningococci. Recombinant expression of 2086 protein enables the use of 2086 protein as an immunogenic composition for the prevention of meningococcal disease. All of the recent meningococcal immunogenic composition candidates in clinical trials have been complex mixtures or outer membrane protein preparations containing many different proteins. The PorA protein, that provides serosubtype specificity, will require the inclusion of 6 to 9 variants in an immunogenic composition to provide about 70-80% coverage of disease related serosubtypes. In contrast, it is clearly demonstrated herein that antisera to a single 2086 protein alone is able to kill representatives of six serosubtypes responsible for about 65% of the disease isolates in western Europe and the United States. Therefore, purified 2086 protein has the potential to reduce the number of proteins required to provide adequate immunogenic composition coverage of the serosubtypes responsible for meningococcal disease. Proteins, Immunogenic Portions and Biological Equivalents
• the 2086 proteins provided by the present invention are isolated proteins or polypeptides.
• isolated means altered by the hand of man from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both.
• a polypeptide or a polynucleotide naturally present in a living animal is not “isolated,” but the same polypeptide or polynucleotide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.
• isolated protein encompasses proteins isolated from a natural source and proteins prepared using recombinant technology, as well as such proteins when combined with other antigens and/or additives, such as pharmaceutically acceptable carriers, buffers, adjuvants, etc., for example.
• the 2086 proteins are characterized as being immunogenic, nonpathogenic and non-strain specific.
• the 2086 proteins are highly variable and thus may undergo insertions, substitutions and/or deletions of amino acid residues without compromising the immunogenicity of the proteins.
• the 2086 proteins may be divided into two subfamilies, Subfamily A and Subfamily B.
• the 2086 proteins from Subfamily A comprise an amino acid sequence of any of the even numbered sequences of SEQ ID NOS:2-6 or an amino acid sequence encoded by a polynucleotide comprising the nucleotide sequence of any of the odd numbered sequences of SEQ ID NOS: 1-5.
• the 2086 proteins from Subfamily B comprise an amino acid sequence of any of the even numbered sequences of SEQ ID NOS:8-12 or an amino acid sequence encoded by a polynucleotide comprising the nucleotide sequence of any of the odd numbered sequences of SEQ ID NOS:7-11.
• a polypeptide sequence of the invention may be identical to the reference sequence (e.g., even numbered SEQ ID NOS:2-12), that is, 100% identical, or it may include a number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%.
• Such alterations include at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion.
• the alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference amino acid sequence or in one or more contiguous groups within the reference amino acid sequence.
• the invention also provides proteins having sequence identity to the amino acid sequences contained in the Sequence Listing (i.e., even numbered SEQ ID NOS:2-12).
• the 2086 protein has a sequence greater than identity of at least about 95%, 96%, 97%, 98%, 99%, 99.9% or more to any of the even numbered amino acid sequences of SEQ ID NOS:2-12.
• the 2086 proteins or other 2086 polypeptides generate bactericidal antibodies to homologous and at least one heterologous strain of meningococci.
• the antibodies to the 2086 polypeptides passively protect infant rats from challenge, such as intranasal, with meningococci.
• the 2086 polypeptides exhibit such protection for infant rats for homologous strains and at least one heterologous strain.
• the polypeptide may be selected from the Sequence Summary above, as set forth in the even numbered SEQ ID NOS: 2-12, or the polypeptide may be any immunological fragment or biological equivalent of the listed polypeptides.
• the polypeptide is selected from any of the even numbered SEQ ID NOS: 2-12 in the Sequence Summary above.
• This invention also relates to allelic or other variants of the 2086 polypeptides, which are biological equivalents. Suitable biological equivalents will exhibit the ability to (1) elicit bactericidal antibodies to homologous strains and at least one heterologous neisserial strain and/or gonococcal strain; (2) react with the surface of homologous strains and at least one heterologous neisserial and/or gonococcal strain; (3) confer passive protection against a live challenge; and/or (4) prevent colonization.
• Suitable biological equivalents have at least about 95 %, 96%, 97% 98%, 99% or 99.9% similarity to one of the 2086 polypeptides specified herein (i.e., the even numbered SEQ ID NOS: 2-12), provided the equivalent is capable of eliciting substantially the same immunogenic properties as one of the 2086 proteins of this invention.
• the biological equivalents have substantially the same immunogenic properties of one of the 2086 proteins in the even numbered SEQ ID NOS: 2- 12. According to embodiments of the present invention, the biological equivalents have the same immunogenic properties as the even numbered SEQ ID NOS: 2-12.
• the biological equivalents are obtained by generating variants and modifications to the proteins of this invention. These variants and modifications to the proteins are obtained by altering the amino acid sequences by insertion, deletion or substitution of one or more amino acids.
• the amino acid sequence is modified, for example by substitution in order to create a polypeptide having substantially the same or improved qualities.
• a preferred means of introducing alterations comprises making predetermined mutations of the nucleic acid sequence of the polypeptide by site-directed mutagenesis.
• Modifications and changes can be made in the structure of a polypeptide of the present invention and still obtain a molecule having N. meningitidis immunogencity.
• certain amino acids can be substituted for other amino acids, including nonconserved and conserved substitution, in a sequence without appreciable loss of immunogenicity. Because it is the interactive capacity and nature of a polypeptide that defines that polypeptide's biological functional activity, a number of amino acid sequence substitutions can be made in a polypeptide sequence (or, of course, its underlying DNA coding sequence) and nevertheless obtain a polypeptide with like properties.
• the present invention contemplates any changes to the structure of the polypeptides herein, as well as the nucleic acid sequences encoding said polypeptides, wherein the polypeptide retains immunogenicity.
• a person of ordinary skill in the art would be readily able to modify the disclosed polypeptides and polynucleotides accordingly, based upon the guidance provided herein.
• any techniques known to persons of skill in the art may be utilized.
• the hydropathic index of amino acids can be considered.
• the importance of the hydropathic amino acid index in conferring interactive biologic function on a polypeptide is generally understood in the art. Kyte ef a/. 1982. J. MoI. Bio. 157:105-132.
• substitution of like amino acids can also be made on the basis of hydrophilicity, particularly where the biological functional equivalent polypeptide or peptide thereby created is intended for use in immunological embodiments.
• U.S. Pat. No. 4,554,101 incorporated herein by reference, states that the greatest local average hydrophilicity of a polypeptide, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity, i.e. with a biological property of the polypeptide.
• Biological equivalents of a polypeptide can also be prepared using site-specific mutagenesis.
• Site-specific mutagenesis is a technique useful in the preparation of second generation polypeptides, or biologically functional equivalent polypeptides or peptides, derived from the sequences thereof, through specific mutagenesis of the underlying DNA. Such changes can be desirable where amino acid substitutions are desirable.
• the technique further provides a ready ability to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA.
• Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed.
• a primer of about 17 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered.
• site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector which includes within its sequence a DNA sequence which encodes all or a portion of the N. meningitidis polypeptide sequence selected.
• An oligonucleotide primer bearing the desired mutated sequence is prepared (e.g., synthetically). This primer is then annealed to the single- stranded vector, and extended by the use of enzymes such as E.
• coli DNA polymerase I Klenow fragment
• This heteroduplex vector is then used to transform appropriate cells such as E. coli cells and clones are selected which include recombinant vectors bearing the mutation.
• kits come with all the reagents necessary, except the oligonucleotide primers.
• 2086 polypeptides include any protein or polypeptide comprising substantial sequence similarity and/or biological equivalence to a 2086 protein having an amino acid sequence from one of the even numbered SEQ ID NOS 2-12.
• a 2086 polypeptide of the invention is not limited to a particular source.
• the invention provides for the general detection and isolation of the polypeptides from a variety of sources.
• the 2086 polypeptides can be prepared recombinantly, as is well within the skill in the art, based upon the guidance provided herein, or in any other synthetic manner, as known in the art.
• a 2086 polypeptide may advantageously be cleaved into fragments for use in further structural or functional analysis, or in the generation of reagents such as 2086-related polypeptides and 2086-specific antibodies.
• This can be accomplished by treating purified or unpurified N. meningitidis polypeptides with a peptidase such as endoproteinase glu-C (Boehringer, Indianapolis, IN). Treatment with CNBr is another method by which peptide fragments may be produced from natural N. meningitidis 2086 polypeptides. Recombinant techniques also can be used to produce specific fragments of a 2086 protein.
• Variant is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties.
• a typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below.
• a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical (i.e., biologically equivalent).
• a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination.
• a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
• a variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.
• Identity is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.
• identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences.
• Identity and similarity can be readily calculated by known methods, including but not limited to those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.
• Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al 1984), BLASTP, BLASTN, and FASTA (Altschul, S. F., et al., 1990).
• the BLASTX program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894; Altschul, S., et al., 1990).
• the well known Smith Waterman algorithm may also be used to determine identity.
• an amino acid sequence of the present invention may be identical to the reference sequences, even numbered SEQ ID NOS: 2-12; that is be 100% identical, or it may include a number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%.
• Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence.
• the number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in even numbered SEQ ID NOS:2-12 by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in any of even numbered SEQ ID NOS:2-12, or:
• n a is the number of amino acid alterations
• x a is the total number of amino acids in even numbered SEQ ID NOS:2-12
• y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of x a and y is rounded down to the nearest integer prior to subtracting it from x a .
• the polypeptide above is selected from the proteins set forth in the even numbered SEQ ID NOS 2-12, such as mature processed form of a 2086 protein.
• the 2086 proteins or equivalents, etc. may be lipidated or non-lipidated.
• ORF 2086 is expressible in E. coli with the native ORF 2086 signal sequence. However, it is desirable to find means to improve the expression of proteins. According to an embodiment of the present invention, a leader sequence produces a lipidated form of the protein. For example, the following describes the use of the signal sequence of the nontypable Haemophilus influenzae P4 protein to enhance expression.
• the processing of bacterial lipoproteins begins with the synthesis of a precursor or prolipoprotein containing a signal sequence, which in turn contains a consensus lipoprotein processing/modification site.
• This prolipoprotein initially passes through the common Sec system on the inner membrane of Gram negative bacteria or on the membrane in Gram positive bacteria. Once placed in the membrane by the Sec system, the prolipoprotein is cleaved by signal peptidase Il at the consensus site and the exposed N- terminal cysteine residue is glycerated and acylated.
• Escherichia coli SecB, SecA, and SecY proteins are required for expression and membrane insertion of the bacteriocin release protein, a small lipoprotein.
• transport of the lipidated protein to the outer membrane is mediated by a unique ABC transporter system with membrane specificity depending on a sorting signal at position 2 of the lipoprotein. Yakushi et al. 2000. A new ABC transporter mediating the detachment of lipid modified proteins from membranes. Nat Cell Biol. Apr;2(4):212-8.
• Bacterial lipidation of proteins is known to increase or modify the immunological response to proteins.
• Bacterial lipoproteins may substitute for cytokines in the humoral immune response to T cell- independent type Il antigens. J. Immunol. Dec 15;155(12):5582-9.
• bacterial lipoprotein expression can be complicated by the stringency of the processing. Pollitt et al. 1986.
• the nontypable Haemophilus influenzae bacterium expresses a lipoprotein designated P4 (also known as protein "e").
• P4 also known as protein "e”
• the recombinant form of the P4 protein is highly expressed in E. coli using the native P4 signal sequence.
• U.S. Patent Number 5,955,580 When the native P4 signal sequence is substituted for the native ORF 2086 signal sequence in an expression vector in E. coli, the level of expression of ORF2086 is increased.
• the non-lipidated form is produced by a protein lacking the original leader sequence or a by a leader sequence which is replaced with a portion of sequence that does not specify a site for fatty acid acylation in a host cell.
• 2086 proteins of this invention are referred to herein as "2086" protein, unless otherwise specifically noted.
• 2086 polypeptide refers to the 2086 proteins as well as immunogenic portions or biological equivalents thereof as noted above, unless otherwise noted.
• N. meningitidis 2086 protein has an apparent molecular weight of about 28 to 35 kDa as measured on a 10 % to 20% gradient SDS polyacrylamide gel (SDS-PAGE). More specifically, this protein has a molecular weight of about 26,000 to 30,000 daltons as measured by mass spectrometry.
• the 2086 polypeptides and nucleic acids encoding such polypeptides are used for preventing or ameliorating infection caused by N. meningitidis and/or other species.
• the proteins of the invention including the amino acid sequences of SEQ ID NOS: 2-12, their fragments, and analogs thereof, or cells expressing them, are also used as immunogens to produce antibodies immunospecific for the polypeptides of the invention.
• the invention includes antibodies to immunospecific polypeptides and the use of such antibodies to detect the presence of N. meningitidis, provide passive protection or measure the quantity or concentration of the polypeptides in a cell, a cell or tissue extract, or a biological fluid.
• the antibodies of the invention include polyclonal antibodies, monoclonal antibodies, chimeric antibodies, and anti-idiotypic antibodies.
• Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen.
• Monoclonal antibodies are a substantially homogeneous population of antibodies to specific antigens.
• Monoclonal antibodies may be obtained by methods known to those skilled in the art, e.g., Kohler and Milstein, 1975, Nature 256:495- 497 and U.S. Patent Number 4,376,110.
• Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, GILD and any subclass thereof.
• Chimeric antibodies are molecules, different portions of which are derived from different animal species, such as those having variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Chimeric antibodies and methods for their production are known in the art (Cabilly et al., 1984, Proc. Natl. Acad. Sci. USA 81 :3273-3277; Morrison et al., 1984, Proc. Natl. Acad. Sci.
• An anti-idiotypic (anti-Id) antibody is an antibody that recognizes unique determinants generally associated with the antigen-binding site of an antibody.
• An anti-Id antibody is prepared by immunizing an animal of the same species and genetic type (e.g., mouse strain) as the source of the monoclonal antibody with the monoclonal antibody to which an anti-Id is being prepared. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing antibody by producing an antibody to these isotypic determinants (the anti-Id antibody).
• monoclonal antibodies generated against the polypeptides of the present invention may be used to induce anti-Id antibodies in suitable animals.
• Spleen cells from such immunized mice can be used to produce anti-Id hybridomas secreting anti-Id monoclonal antibodies.
• the anti-Id antibodies can be coupled to a carrier such as keyhole limpet hemocyanin (KLH) and used to immunize additional BALB/c mice.
• Sera from these mice will contain anti-anti-ld antibodies that have the binding properties of the final mAb specific for an R-PTPase epitope.
• the anti-Id antibodies thus have their idiotypic epitopes, or "idiotopes" structurally similar to the epitope being evaluated, such as Streptococcus pyogenes polypeptides.
• antibody is also meant to include both intact molecules as well as fragments such as Fab, single chain antibodies and other antigen-recognizing fragments of antibodies which are capable of binding antigen.
• Fab fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl et a/., 1983, J. Nucl. Med. 24:316-325). It will be appreciated that Fab and other fragments of the antibodies useful in the present invention may be used for the detection and quantitation of N. meningitidis polypeptides according to the methods for intact antibody molecules.
• the antibodies of this invention can be employed in a method for the treatment or prevention of Neisseria infection in mammalian hosts, which comprises administration of an immunologically effective amount of antibody, specific for a polypeptide as described above.
• the anti-Id antibody may also be used as an "immunogen" to induce an immune response in yet another animal, producing a so-called anti-anti-ld antibody.
• the anti-anti-ld may be epitopically identical to the original mAb that induced the anti-Id.
• the antibodies are used in a variety of ways, e.g., for confirmation that a protein is expressed, or to confirm where a protein is expressed.
• Labeled antibody e.g., fluorescent labeling for FACS
• FACS fluorescent labeling for FACS
• Antibodies generated against the polypeptides of the invention can be obtained by administering the polypeptides or epitope-bearing fragments, analogs, or cells to an animal using routine protocols.
• any technique that provides antibodies produced by continuous cell line cultures are used.
• a polynucleotide of the present invention may comprise a nucleic acid sequence that is identical to any of the reference sequences of odd numbered SEQ ID NOS:1-11 , that is be 100% identical, or it may include up to a number of nucleotide alterations as compared to the reference sequence.
• Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3 1 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
• the number of nucleotide alterations is determined by multiplying the total number of nucleotides in any of odd numbered SEQ ID NOS:1-11 by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from said total number of nucleotides in said sequence.
• an isolated N. meningitidis polynucleotide comprising a polynucleotide sequence that has at least 95% identity to any nucleic acid sequence of odd numbered SEQ ID NOS:1-11 ; a degenerate variant thereof or a fragment thereof, wherein the polynucleotide sequence may include up to n n nucleic acid alterations over the entire polynucleotide region of the nucleic acid sequence of odd numbered SEQ ID NOS:1-11 , wherein n n is the maximum number of alterations and is calculated by the formula:
• X n is the total number of nucleic acids of any of odd numbered SEQ ID NOS: 1-11 and y has a value of 0.95, wherein any non-integer product of X n and y is rounded down to the nearest integer prior to subtracting such product from X n .
• y may also have a value of 0.95 for 95%, etc.
• Alterations of a polynucleotide sequence encoding the polypeptides comprising amino acid sequences of any of even numbered SEQ ID NOS:2-12 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.
• an isolated polynucleotide of the present invention is a polynucleotide comprising a nucleotide sequence having at least about 95% identity to a nucleotide sequence chosen from one of the odd numbered SEQ ID NOS: 1-11 , a degenerate variant thereof, or a fragment thereof.
• a "degenerate variant” is defined as a polynucleotide that differs from the nucleotide sequence shown in the odd numbered SEQ ID NOS:1-11 (and fragments thereof) due to degeneracy of the genetic code, but still encodes the same 2086 protein (e.g., the even numbered SEQ ID NOS: 2-12) as that encoded by the nucleotide sequence shown in the odd numbered SEQ ID NOS: 1-11.
• the polynucleotide is a complement to a nucleotide sequence chosen from one of the odd numbered SEQ ID NOS: 1-11 , a degenerate variant thereof, or a fragment thereof.
• the polynucleotide is selected from the group consisting of DNA, chromosomal DNA, cDNA and RNA and may further comprises heterologous nucleotides.
• the 2086 polynucleotides may be obtained from natural, synthetic or semi-synthetic sources; furthermore, the nucleotide sequence may be a naturally occurring sequence, or it may be related by mutation, including single or multiple base substitutions, deletions, insertions and inversions, to such a naturally occurring sequence, provided always that the nucleic acid molecule comprising such a sequence is capable of being expressed as 2086 immunogenic polypeptide as described above.
• the nucleic acid molecule may be RNA, DNA, single stranded or double stranded, linear or covalently closed circular form.
• the nucleotide sequence may have expression control sequences positioned adjacent to it, such control sequences usually being derived from a heterologous source. Generally, recombinant expression of the nucleic acid sequence of this invention will use a stop codon sequence, such as TAA, at the end of the nucleic acid sequence.
• the invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein.
• stringency conditions are shown in the Stringency Conditions Table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.
• the hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides.
• the hybrid length is assumed to be that of the hybridizing polynucleotide.
• the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarities.
• SSPE (IxSSPE is 0.15M NaCI, 1OmM NaH 2 PO 4 , and 1.25mM EDTA, pH 7.4) can be substituted for SSC (IxSSC is 0.15M NaCI and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.
• the invention also provides polynucleotides that are fully complementary to these polynucleotides and also provides antisense sequences.
• the antisense sequences of the invention also referred to as antisense oligonucleotides, include both internally generated and externally administered sequences that block expression of polynucleotides encoding the polypeptides of the invention.
• the antisense sequences of the invention comprise, for example, about 15-20 base pairs.
• the antisense sequences can be designed, for example, to inhibit transcription by preventing promoter binding to an upstream nontranslated sequence or by preventing translation of a transcript encoding a polypeptide of the invention by preventing the ribosome from binding.
• polynucleotides of the invention are prepared in many ways (e.g., by chemical synthesis, from DNA libraries, from the organism itself) and can take various forms (e.g., single-stranded, double-stranded, vectors, probes, primers).
• polynucleotide includes DNA and RNA, and also their analogs, such as those containing modified backbones.
• the polynucleotides of the present invention comprise a DNA library, such as a cDNA library.
• the present invention also relates to fusion proteins.
• a "fusion protein” refers to a protein encoded by two, often unrelated, fused genes or fragments thereof.
• fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another immunogenic protein or part thereof.
• employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties (see, e.g., EP 0 232 262 A1 ).
• the 2086 polynucleotides of the invention are used for the recombinant production of polypeptides of the present invention
• the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre- , or pro- or prepro- protein sequence, or other fusion peptide portions.
• a marker sequence which facilitates purification of a 2086 polypeptide or fused polypeptide can be encoded (see Gentz et al., 1989, incorporated herein by reference in its entirety).
• contemplated in an implementation of the present invention is the preparation of polynucleotides encoding fusion polypeptides permitting His-tag purification of expression products.
• the polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals.
• Such a fused polypeptide can be produced by a host cell transformed/transfected or infected or infected with a recombinant DNA cloning vehicle as described below and it can be subsequently isolated from the host cell to provide the fused polypeptide substantially free of other host cell proteins.
• One aspect of the present invention provides immunogenic compositions which comprise at least one 2086 proteins or a nucleic acid encoding said proteins.
• the foregoing have the ability to (1) elicit bactericidal antibodies to multiple strains; (2) react with the surface of multiple strains; (3) confer passive protection against a live challenge; and/or (4) prevent colonization.
• the formulation of such immunogenic compositions is well known to persons skilled in this field.
• the compositions of the invention include a pharmaceutically acceptable carrier and/or diluent.
• Suitable pharmaceutically acceptable carriers and/or diluents include any and all conventional solvents, dispersion media, fillers, solid carriers, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
• Suitable pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof.
• Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibody.
• the preparation and use of pharmaceutically acceptable carriers is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the immunogenic compositions of the present invention is contemplated.
• the pharmaceutically acceptable carrier is a carrier protein.
• Carrier proteins are preferably proteins that are non-toxic and non-reactogenic and obtainable in sufficient amount and purity. Carrier proteins should be amenable to standard conjugation procedures.
• CRM 197 is used as the carrier protein.
• CRM 197 (Wyeth, Sanford, NC) is a non-toxic variant (i.e., toxoid) of diphtheria toxin isolated from cultures of Corynebacterium diphtheria strain C7 ( ⁇ 197) grown in casamino acids and yeast extract-based medium.
• CRM 197 is purified through ultra-filtration, ammonium sulfate precipitation, and ion-exchange chromatography. Another method of obtaining CRM 197 is described in U.S. Patent No. 4,925,792.
• CRM 197 is prepared recombinantly in accordance with U.S. Patent No. 5,614,382.
• Other diphtheria toxoids are also suitable for use as carrier proteins.
• a carrier protein of the invention is an enzymatically inactive streptococcal C5a peptidase (SCP) (e.g., one or more of the SCP variants described in U.S. Patent Nos. 6,270,775, 6,355,255 and 6,951 ,653).
• SCP streptococcal C5a peptidase
• Suitable carrier proteins include inactivated bacterial toxins such as tetanus toxoid, pertussis toxoid, cholera toxoid (e.g., CT E29H, described in International PCT Publication No. WO2004/083251), E coli LT, E coli ST, E. coli DnaK protein, and exotoxin A from Pseudomonas aeruginosa.
• Bacterial outer membrane proteins such as outer membrane complex c (OMPC), porins, transferrin binding proteins, pneumolysin toxin (e.g., U.S. Patent No.
• pneumolysin toxoid e.g., International PCT Publication No. WO2005/108580
• pneumococcal surface protein A PspA
• pneumococcal adhesin protein PsaA
• Haemophilus influenzae protein D can also be used.
• Bacterial heat shock proteins such as mycobacterial hsp-70 can also be used.
• Other proteins such as Staphylococcus epidermidis proteins SdrG, SitC and ferrochrome binding proteins, and Staphylococcus aureus proteins CIfA, CIfB and FnbA can also be used.
• Still other proteins such as ovalbumin, keyhole limpet haemocyanin (KLH), glutathione S-transferase (GST), bovine serum albumin (BSA), galactokinase (galK), ubiquitin, ⁇ -galactosidase, influenza NS1 protein, or purified protein derivative of tuberculin (PPD) can also be used as carrier proteins.
• Virus-like particles for example from rotavirus VP6 or from bacteriophage Q ⁇ , can also be used.
• Immunogenic compositions as described herein also comprise, in certain embodiments, one or more adjuvants.
• An adjuvant is a substance that enhances the immune response when administered together with an immunogen or antigen.
• a number of cytokines or lymphokines have been shown to have immune modulating activity, and thus are useful as adjuvants, including, but not limited to, the interleukins 1- ⁇ , 1- ⁇ , 2, 4, 5, 6, 7, 8, 10, 12 (see, e.g., U.S. Patent No. 5,723,127), 13, 14, 15, 16, 17 and 18 (and its mutant forms); the interferons- ⁇ , ⁇ and Y; granulocyte-macrophage colony stimulating factor (GM- CSF) (see, e.g., U.S.
• GM- CSF granulocyte-macrophage colony stimulating factor
• chemokines including without limitation, MCP-1 , MIP-1 ⁇ , MIP-1 ⁇ , and RANTES; adhesion molecules, such as a selectin, e.g., L-selectin, P-selectin and E-selectin; mucin-like molecules, e.g., CD34, GlyCAM-1 and MadCAM-1 ; a member of the integrin family such as LFA-1 , VLA-1 , Mac-1 and p150.95; a member of the immunoglobulin superfamily such as PECAM, ICAMs, e.g., ICAM-1 , ICAM-2 and ICAM-3, CD2 and LFA-3; co-stimulatory molecules such as
• Suitable adjuvants used to enhance an immune response further include, without limitation, MPLTM (3-O-deacylated monophosphoryl lipid A, Corixa, Hamilton, MT) 1 which is described in U.S. Patent No. 4,912,094.
• MPLTM 3-O-deacylated monophosphoryl lipid A, Corixa, Hamilton, MT
• lipid A analogs or aminoalkyl glucosamine phosphate compounds AGP
• AGP aminoalkyl glucosamine phosphate compounds
• One such AGP is 2-[(R)-3-
• This 529 adjuvant is formulated as an aqueous form (AF) or as a stable emulsion (SE).
• Still other adjuvants include muramyl peptides, such as N-acetyl-muramyl-L- threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanine-2-(1'-2' dipalmitoyl-sn- glycero-3-hydroxyphosphoryloxy)-ethylarnine (MTP-PE); oil-in-water emulsions, such as MF59 (International PCT Publication No.
• muramyl peptides such as N-acetyl-muramyl-L- threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanine-2-(1'-2' dipalmitoyl-sn- glycero-3-hydroxyphosphoryloxy)-ethylarnine (MTP-PE); oil-in-water
• WO 90/14837 (containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA)), and SAF (containing 10% Squalene, 0.4% Tween 80, 5% pluronic-blocked polymer L121 , and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion); incomplete Freund's adjuvant (IFA); aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate; Amphigen; Avridine; L121/squalene; D-lactide-polylactide/glycoside; pluronic polyols; killed Bordetella; saponins, such as StimulonTM QS-21 (
• a pertussis toxin (PT) or mutant thereof, a cholera toxin or mutant thereof e.g., International PCT Publication Nos. WOOO/18434, WO02/098368 and WO02/098369
• LT E. coli heat-labile toxin
• LT particularly LT-K63, LT-R72, PT- K9/G129; see, e.g., International PCT Publication Nos. WO 93/13302 and WO 92/19265.
• Such immunogenic compositions can be administered parenterally, e.g., by injection, either subcutaneously or intramuscularly, as well as orally or intranasally. Methods for intramuscular immunization are described by Wolff et al. and by Sedegah et at. Other modes of administration employ oral formulations, pulmonary formulations, suppositories, and transdermal applications, for example, without limitation. Oral formulations, for example, include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like, without limitation.
• the immunogenic compositions of this invention may be delivered in the form of ISCOMS (immune stimulating complexes), ISCOMS containing CTB, liposomes or encapsulated in compounds such as acrylates or poly(DL-lactide-co-glycoside) to form microspheres of a size suited to adsorption.
• ISCOMS immune stimulating complexes
• ISCOMS containing CTB liposomes
• encapsulated in compounds such as acrylates or poly(DL-lactide-co-glycoside) to form microspheres of a size suited to adsorption.
• the proteins of this invention may also be incorporated into oil emulsions.
• the immunogenic agents including proteins, polynucleotides and equivalents of the present invention may be administered as the sole active immunogen in a immunogenic composition, or alternatively, the composition may include other active immunogens, including other Neisseria sp. immunogenic polypeptides, or immunologically-active proteins of one or more other microbial pathogens (e.g. virus, prion, bacterium, or fungus, without limitation) or capsular polysaccharide.
• the compositions may comprise one or more desired proteins, fragments or pharmaceutical compounds as desired for a chosen indication.
• the compositions of this invention which employ one or more nucleic acids in the immunogenic composition may also include nucleic acids which encode the same diverse group of proteins, as noted above.
• compositions of the present invention may a comprise combinations of two or more 2086 proteins, a combination of 2086 protein with one or more Por A proteins, a combination of 2086 protein with meningococcus serogroup A, C, Y and W135 polysaccharides and/or polysaccharide conjugates, a combination of 2086 protein with meningococcus and pneumococcus combinations, or a combination of any of the foregoing in a form suitable for mucosal delivery.
• Persons of skill in the art would be readily able to formulate such multi-antigen or multi-valent immunologic compositions.
• the present invention also contemplates multi-immunization regimens wherein any composition useful against a pathogen may be combined therein or therewith the compositions of the present invention.
• a patient may be administered the immunogenic composition of the present invention and another immununological composition for immunizing against S. Pneumoniae, as part of a multi- immunization regimen.
• an immununological composition for immunizing against S. Pneumoniae as part of a multi- immunization regimen.
• Persons of skill in the art would be readily able to select immunogenic compositions for use in conjunction with the immunogenic compositions of the present invention for the purposes of developing and implementing multi-immunization regimens.
• Specific embodiments of this invention relate to the use of one or more polypeptides of this invention, or nucleic acids encoding such, in a composition or as part of a treatment regimen for the prevention or amelioration of S. pneumoniae infection.
• the 2086 polypeptides, fragments and equivalents can be used as part of a conjugate immunogenic composition; wherein one or more proteins or polypeptides are conjugated to a carrier protein in order to generate a composition that has immunogenic properties against several serotypes and/or against several diseases.
• one of the 2086 polypeptides can be used as a carrier protein for other immunogenic polypeptides.
• the present invention also relates to a method of inducing immune responses in a mammal comprising the step of providing to said mammal an immunogenic composition of this invention.
• the immunogenic composition is a composition which is antigenic in the treated animal or human such that the immunologically effective amount of the polypeptide(s) contained in such composition brings about the desired immune response against N. meningitidis infection.
• Preferred embodiments relate to a method for the treatment, including amelioration, or prevention of N. meningitidis infection in a human comprising administering to a human an immunologically effective amount of the composition.
• the phrase "immunologically effective amount,” as used herein, refers to the administration of that amount to a mammalian host (preferably human), either in a single dose or as part of a series of doses, sufficient to at least cause the immune system of the individual treated to generate a response that reduces the clinical impact of the bacterial infection. This may range from a minimal decrease in bacterial burden to prevention of the infection. Ideally, the treated individual will not exhibit the more serious clinical manifestations of the bacterial infection.
• the dosage amount can vary depending upon specific conditions of the individual. This amount can be determined in routine trials or otherwise by means known to those skilled in the art.
• Another specific aspect of the present invention relates to using as the immunogenic composition a vector or plasmid that expresses an protein of this invention, or an immunogenic portion thereof.
• this invention provides a method of inducing an immune response in a mammal, which comprises providing to a mammal a vector or plasmid expressing at least one isolated 2086 polypeptide.
• the protein of the present invention can be delivered to the mammal using a live vector, in particular using live recombinant bacteria, viruses or other live agents, containing the genetic material necessary for the expression of the polypeptide or immunogenic portion as a foreign polypeptide.
• a method for diagnosing bacterial meningitis in a mammal comprising: detecting the presence of immune complexes in the mammal or a tissue sample from said mammal, said mammal or tissue sample being contacted with an antibody composition comprising antibodies that immunospecifically bind with at least one polypeptide comprising the amino acid sequence of any of the even numbered SEQ ID NOS: 2-12; wherein the mammal or tissue sample is contacted with the antibody composition under conditions suitable for the formation of the immune complexes.
• Preferred vectors are viral vectors, such as Antiviruses, retroviruses, herpes viruses, adenoviruses, adeno-associated viruses, vaccinia virus, baculovirus, and other recombinant viruses with desirable cellular tropism.
• viral vectors such as Antiviruses, retroviruses, herpes viruses, adenoviruses, adeno-associated viruses, vaccinia virus, baculovirus, and other recombinant viruses with desirable cellular tropism.
• a nucleic acid encoding a 2086 protein or immunogenic fragment thereof can be introduced in vivo, ex vivo, or in vitro using a viral vector or through direct introduction of DNA.
• Expression in targeted tissues can be effected by targeting the transgenic vector to specific cells, such as with a viral vector or a receptor ligand, or by using a tissue-specific promoter, or both. Targeted gene delivery is described in PCT Publication No. WO 95/2
• Viral vectors commonly used for in vivo or ex vivo targeting and therapy procedures are DNA-based vectors and retroviral vectors. Methods for constructing and using viral vectors are known in the art (e.g., Miller and Rosman, BioTechniques, 1992, 7:980-990).
• the viral vectors are replication-defective, that is, they are unable to replicate autonomously in the target cell.
• the replication defective virus is a minimal virus, i.e., it retains only the sequences of its genome which are necessary for encapsulating the genome to produce viral particles.
• DNA viral vectors include an attenuated or defective DNA virus, such as but not limited to herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like.
• HSV herpes simplex virus
• EBV Epstein Barr virus
• AAV adeno-associated virus
• Defective viruses which entirely or almost entirely lack viral genes, are preferred. Defective virus is not infective after introduction into a cell.
• Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Thus, a specific tissue can be specifically targeted.
• particular vectors include, but are not limited to, a defective herpes virus 1 (HSV1) vector (Kaplitt et al., Molec. Cell.
• viral vectors commercially, including, but not limited to, Avigen, Inc. (Alameda, CA; AAV vectors), Cell Genesys (Foster City, CA; retroviral, adenoviral, AAV vectors, and lentiviral vectors), Clontech (retroviral and baculoviral vectors), Genovo, Inc.
• Avigen, Inc. Almeda, CA; AAV vectors
• Cell Genesys Fester City, CA; retroviral, adenoviral, AAV vectors, and lentiviral vectors
• Clontech retroviral and baculoviral vectors
• Adenovirus vectors are eukaryotic DNA viruses that can be modified to efficiently deliver a nucleic acid of this invention to a variety of cell types.
• Various serotypes of adenovirus exist. Of these serotypes, preference is given, within the scope of the present invention, to using type 2 or type 5 human adenoviruses (Ad 2 or Ad 5) or adenoviruses of animal origin (see PCT Publication No. WO 94/26914).
• adenoviruses of animal origin which can be used within the scope of the present invention include adenoviruses of canine, bovine, murine (example: Mav1 , Beard et al., Virology, 1990, 75-81), ovine, porcine, avian, and simian (example: SAV) origin.
• the adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus (e.g., Manhattan or A26/61 strain, ATCC VR-800, for example).
• CAV2 adenovirus e.g., Manhattan or A26/61 strain, ATCC VR-800, for example.
• the replication defective recombinant adenoviruses according to the invention can be prepared by any technique known to the person skilled in the art (Levrero et al., Gene, 1991 , 101 :195; European Publication No. EP 185 573; Graham, EMBO J., 1984, 3:2917; Graham et al., J. Gen. Virol., 1977, 36:59). Recombinant adenoviruses are recovered and purified using standard molecular biological techniques, which are well known to persons of ordinary skill in the art.
• Adeno-associated viruses are DNA viruses of relatively small size that can integrate, in a stable and site-specific manner, into the genome of the cells that they infect. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation, and they do not appear to be involved in human pathologies.
• the AAV genome has been cloned, sequenced and characterized. The use of vectors derived from the AAVs for transferring genes in vitro and in vivo has been described (see, PCT Publication Nos. WO 91/18088 and WO 93/09239; U.S. Patent Nos.
• the replication defective recombinant AAVs according to the invention can be prepared by cotransfecting a plasmid containing the nucleic acid sequence of interest flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsidation genes (rep and cap genes), into a cell line which is infected with a human helper virus (for example an adenovirus).
• ITR inverted terminal repeat
• rep and cap genes AAV encapsidation genes
• the AAV recombinants that are produced are then purified by standard techniques.
• Retrovirus vectors In another implementation of the present invention, the nucleic acid can be introduced in a retroviral vector, e.g., as described in U.S. Patent No. 5,399,346; Mann et al., Cell, 1983, 33:153; U.S. Patent Nos. 4,650,764 and 4,980,289; Markowitz et al., J. Virol., 1988, 62:1120; U.S. Patent No. 5,124,263; European Publication Nos. EP 453 242 and EP178 220; Bernstein et al., Genet. Eng., 1985, 7:235; McCormick, BioTechnology, 1985, 3:689; PCT Publication No.
• the retroviruses are integrating viruses that infect dividing cells.
• the retrovirus genome includes two LTRs, an encapsidation sequence and three coding regions (gag, pol and env).
• the gag, pol and env genes are generally deleted, in whole or in part, and replaced with a heterologous nucleic acid sequence of interest.
• vectors can be constructed from different types of retrovirus, such as, HIV, MoMuLV ("murine Moloney leukaemia virus” MSV ("murine Moloney sarcoma virus”), HaSV ("Harvey sarcoma virus”); SNV ("spleen necrosis virus”); RSV ("Rous sarcoma virus”) and Friend virus.
• Suitable packaging cell lines have been described in the prior art, in particular the cell line PA317 (U.S. Patent No. 4,861 ,719); the PsiCRIP cell line (PCT Publication No. WO 90/02806) and the GP+envAm-12 cell line (PCT Publication No. WO 89/07150).
• the recombinant retroviral vectors can contain modifications within the LTRs for suppressing transcriptional activity as well as extensive encapsidation sequences which may include a part of the gag gene (Bender et al., J. Virol., 1987, 61 :1639).
• Recombinant retroviral vectors are purified by standard techniques known to those having ordinary skill in the art.
• Retroviral vectors can be constructed to function as infectious particles or to undergo a single round of transfection. In the former case, the virus is modified to retain all of its genes except for those responsible for oncogenic transformation properties, and to express the heterologous gene. Non-infectious viral vectors are manipulated to destroy the viral packaging signal, but retain the structural genes required to package the co-introduced virus engineered to contain the heterologous gene and the packaging signals. Thus, the viral particles that are produced are not capable of producing additional virus.
• Retrovirus vectors can also be introduced by DNA viruses, which permits one cycle of retroviral replication and amplifies transfection efficiency (see PCT Publication Nos. WO 95/22617, WO 95/26411 , WO 96/39036 and WO 97/19182).
• Lentivirus vectors in another implementation of the present invention, can be used as agents for the direct delivery and sustained expression of a transgene in several tissue types, including brain, retina, muscle, liver and blood. The vectors can efficiently transduce dividing and nondividing cells in these tissues, and effect long-term expression of the gene of interest.
• Lentiviral packaging cell lines are available and known generally in the art. They facilitate the production of high-titer lentivirus vectors for gene therapy.
• An example is a tetracycline-inducible VSV-G pseudotyped lentivirus packaging cell line that can generate virus particles at titers greater than 106 IU/mL for at least 3 to 4 days (Kafri, et ai, J. Virol., 1999, 73: 576-584).
• the vector produced by the inducible cell line can be concentrated as needed for efficiently transducing non-dividing cells in vitro and in vivo.
• Non-viral vectors In another implementation of the present invention, the vector can be introduced in vivo by lipofection, as naked DNA, or with other transfection facilitating agents (peptides, polymers, etc.). Synthetic cationic lipids can be used to prepare liposomes for in vivo transfection of a gene encoding a marker (Feigner, et. al., Proc. Natl. Acad. Sci. U.S.A., 1987, 84:7413-7417; Feigner and Ringold, Science, 1989, 337:387-388; see Mackey, et al., Proc. Natl. Acad. Sci.
• lipid compounds and compositions for transfer of nucleic acids are described in PCT Patent Publication Nos. WO 95/18863 and WO 96/17823, and in U.S. Patent No. 5,459,127.
• Lipids may be chemically coupled to other molecules for the purpose of targeting (see Mackey, et. al., supra).
• Targeted peptides e.g., hormones or neurotransmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to liposomes chemically.
• a nucleic acid in vivo, is also useful for facilitating transfection of a nucleic acid in vivo, such as a cationic oligopeptide (e.g., PCT Patent Publication No. WO 95/21931), peptides derived from DNA binding proteins (e.g., PCT Patent Publication No. WO 96/25508), or a cationic polymer (e.g., PCT Patent Publication No. WO 95/21931).
• a cationic oligopeptide e.g., PCT Patent Publication No. WO 95/21931
• peptides derived from DNA binding proteins e.g., PCT Patent Publication No. WO 96/25508
• a cationic polymer e.g., PCT Patent Publication No. WO 95/21931
• DNA vectors for vaccine purposes or gene therapy can be introduced into the desired host cells by methods known in the art, e.g., electroporation, microinjection, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter (e.g., Wu et al., J. Biol. Chem., 1992, 267:963-967; Wu and Wu, J. Biol. Chem., 1988, 263:14621-14624; Canadian Patent Application No. 2,012,311 ; Williams et al., Proc. Natl. Acad. Sci. USA, 1991 , 88:2726-2730).
• Receptor-mediated DNA delivery approaches can also be used (Curiel et al., Hum. Gene Then, 1992, 3:147-154; Wu and Wu, J. Biol.
• U.S. Patent Nos. 5,580,859 and 5,589,466 disclose delivery of exogenous DNA sequences, free of transfection facilitating agents, in a mammal. Recently, a relatively low voltage, high efficiency in vivo DNA transfer technique, termed electrotransfer, has been described (Mir et al. , CP. Acad. Sci., 1988, 321 :893; PCT Publication Nos. WO 99/01157; WO 99/01158; WO 99/01175).
• additional embodiments of the present invention relates to a method of inducing an immune response in a human comprising administering to said human an amount of a DNA molecule encoding a 2086 polypeptide of this invention, optionally with a transfection-facilitating agent, where said polypeptide, when expressed, retains immunogenicity and, when incorporated into an immunogenic composition and administered to a human, provides protection without inducing enhanced disease upon subsequent infection of the human with Neisseria sp. pathogen, such as N. meningitidis.
• Transfection-facilitating agents are known in the art and include bupivicaine, and other local anesthetics (for examples see U.S. Patent No. 5,739,118) and cationic polyamines (as published in International Patent Application WO 96/10038), which are hereby incorporated by reference.
• the present invention also relates to an antibody, which may either be a monoclonal or polyclonal antibody, specific for 2086 polypeptides as described above.
• an antibody which may either be a monoclonal or polyclonal antibody, specific for 2086 polypeptides as described above.
• Such antibodies may be produced by methods that are well known to those skilled in the art.
• This invention also provides a recombinant DNA molecule, such as a vector or plasmid, comprising an expression control sequence having promoter sequences and initiator sequences and a nucleotide sequence which codes for a polypeptide of this invention, the nucleotide sequence being located 3' to the promoter and initiator sequences.
• a recombinant DNA cloning vehicle capable of expressing a 2086 polypeptide comprising an expression control sequence having promoter sequences and initiator sequences, and a nucleotide sequence which codes for a 2086 polypeptide, the nucleotide sequence being located 3' to the promoter and initiator sequences.
• a host cell containing a recombinant DNA cloning vehicle and/or a recombinant DNA molecule as described above.
• Suitable expression control sequences and host cell/cloning vehicle combinations are well known in the art, and are described by way of example, in Sambrook et al. (1989).
• recombinant DNA cloning vehicles and/or host cells expressing a desired a polypeptide of this invention have been constructed by transforming, transfecting or infecting such cloning vehicles or host cells with plasmids containing the corresponding 2086 polynucleotide, cloning vehicles or host cells are cultured under conditions such that the polypeptides are expressed. The polypeptide is then isolated substantially free of contaminating host cell components by techniques well known to those skilled in the art.
• LOS lipid oligosacharride-depleted outer membrane protein preparations have been shown to elicit bactericidal antibodies. These antibodies are often directed towards the PorA of the respective strain. LOS-depleted outer membrane preparations from serogroup B meningococcal strain 8529 (B:15:P1.7b,3) are unusual in this manner because they unexpectedly elicit bactericidal antibodies to several heterologous strains. TABLE Il BC ACTIVITY OF ANTI-SOMPS AGAINST DIFFERENT STRAINS OF N. MENINGITIDIS [0163] To facilitate the isolation and characterization of the antigen(s) responsible for eliciting heterologous bactericidal antibodies, we sought to identify which detergent optimally extracted the antigen(s)
• N. meningitidis strain 8529 from a frozen vial was streaked onto a GC plate.
• the meningococcal strain 8529 was received from The RIVM, Bilthoven, The Netherlands).
• the plate was incubated at 36C/5%CO 2 for 7.5hours.
• Several colonies were used to inoculate a flask containing 50 ml_ of modified Frantz medium + GC supplement.
• the flask was incubated in an air shaker at 36°C and agitated at 200 RPM for 4.5hours. 5 ml. was used to inoculate a Fernbach flask containing 450 ml. of modified Frantz medium + GC supplement.
• the flask was incubated in an air shaker at 36°C and agitated at 100 RPM for 11 hours.
• the entire 450 ml_ was used to inoculate 8.5 L of modified Frantz medium ⁇ GC supplement in a 10 L fermentor.
• the cell envelopes were then extracted with 32OmL of 1% (w/v) Triton X-100 in 1OmM HEPES-NaOH, pH 7.4, 1 mM MgCI 2 .
• Table III results from sequential differential detergent extractions using Triton X-100 and Zwittergent 3-14 followed by immunization of mice, allowed us to determine that the Triton extracts optimally extracted the candidate(s) of interest.
• This Triton X-100 extract eliciting bactericidal antibody response against four out of five strains listed in Table III, was then fractionated by preparative isoelectric focusing (IEF) in a BioRad Rotophor unit.
• Ampholyte concentrations were 1% pH 3-10 mixed with 1 % pH 4-6. As shown in Table III, several fractions were found to elicit a heterologous bactericidal response. The fractions obtained from IEF, which focused in the pH range of 5.5-7.8, elicited a heterologous response to the most strains as determined by the bactericidal assay. The pooled IEF fractions were concentrated and the ampholytes removed by ethanol precipitation. A further purification was achieved by adsorbing some of the proteins obtained in the pH range of about 5.5-7.8 on an anion exchange column and comparing the bactericidal activity obtained after immunizing mice with the adsorbed and unadsorbed proteins. Referring again to Table II, while many proteins were adsorbed to the anion exchange resin, the proteins that were not adsorbed by the column elicited more heterologous bactericidal antibodies. TABLE
• FIG. 1A two major proteins were present in the unadsorbed fraction as determined by SDS-PAGE. To identify these proteins, two types of analysis were performed. One analysis was to perform limited proteolytic degradation (See FIG. 1A, and FIG. 1B) followed by isolation of peptides and direct protein sequencing. The other analysis was to perform SDS-PAGE followed by gel excision, proteolytic digestion, and LC-MS/MS (Liquid Chromotography tandem Mass Spectrometry), (see FIG. 3) to obtain mass spectral information on the components of the preparations of interest. (See peptide mapping and sequencing methods described later in this section)
• ORF 4431 was the most predominant protein identified in the fractions, mouse antibodies to recombinant lipidated 4431 were not bactericidal and did not provide a protective response in an animal model. Additional analysis of ORF 5163 is in progress.
• AEUF Cyanogen Bromide cleavage of Anion Exchange Unadsorbed Fraction
• the AEUF was digested with GIuC (V8), LysC or ArgC.
• the protein to enzyme ratio was 30 ⁇ g protein to 1 ⁇ g enzyme. The digestion was carried out at 37°C overnight.
• the digested protein mixture (30 ⁇ g) was passed over a seven micron Aquapore RF-300 column and was eluted with a gradient of 10-95% acetonitrile in 0.1 % trifluoroacetic acid, and peaks were collected manually. A no protein blank was also run, and the peaks from this were subtracted from the sample chromatogram. Peaks occurring only in the sample run were analyzed by mass spectrometer, and those samples giving a clear mass were analyzed for N-terminal amino acid sequencing.
• the protein sample was transferred from an SDS gel to a PVDF membrane, stained with Amido Black (10% acetic acid, 0.1% amido black in deionized water) and destained in 10% acetic acid.
• Amido Black (10% acetic acid, 0.1% amido black in deionized water) and destained in 10% acetic acid.
• the desired protein band was then excised from all ten lanes using a methanol cleaned scalpel or mini-Exacto knife and placed in the reaction cartridge of the Applied Biosystems 477A Protein Sequencer.
• the Prosorb cartridge was assembled and the PVDF wetted with 60 ⁇ l_ of methanol. The PVDF was rinsed with 50 ⁇ l_ of deionized water and the sample (50 ⁇ l_) was loaded to the PVDF.
• the Prosorb PVDF was punched out, dried, and placed in the reaction cartridge of the Applied Biosystems 477A Protein Sequencer.
• the Applied Biosystems N-terminal Sequencer was then run under optimal blot conditions for 12 or more cycles (1 cycle Blank, 1 cycle Standard, and 10 or more cycles for desired residue identification) and PTH-amino acid detection was done on the Applied Biosystems 120A PTH Analyzer. The cycles were collected both on an analog chart recorder and digitally via the instrument software.
• Amino acid assignment was done using the analog and digital data by comparison of a standard set of PTH-amino acids and their respective retention times on the analyzer (cysteine residues were destroyed during conversion and were not detected). Multiple sequence information can be obtained from a single residue and primary versus secondary assignments were made based on signal intensity.
• Protein samples purified by IEF were further analyzed by SDS-polyacrylamide gel electrophoresis. Proteins were visualized by Coomaasie blue staining, and bands of interest were excised manually, then reduced, alkylated and digested with trypsin (Promega, Madison, Wl) in situ using an automated in-gel tryptic digestion robot (1). After digestion, peptide extracts were concentrated to a final volume of 10-20 ⁇ l_ using a Savant Speed Vac Concentrator (ThermoQuest, Holdbrook, NY).
• Peptide extracts were analyzed on an automated microelectrospray reversed phase HPLC.
• the microelectrospray interface consisted of a Picofrit fused silica spray needle, 50 cm length by 75 urn ID, 8um orifice diameter (New Objective, Cambridge MA) packed with 10 urn C18 reversed-phase beads (YMC, Wilmington, NC) to a length of 10 cm.
• the Picofrit needle was mounted in a fiber optic holder (Melles Griot, Irvine, CA) held on a home-built base positioned at the front of the mass spectrometer detector. The rear of the column was plumbed through a titanium union to supply an electrical connection for the electrospray interface.
• the union was connected with a length of fused silica capillary (FSC) tubing to a FAMOS autosampler (LC-Packings, San Francisco, CA) that was connected to an HPLC solvent pump (ABI 140C, Perkin-Elmer, Norwalk, CT).
• HPLC solvent pump delivered a flow of 50 ⁇ L /min which was reduced to 250 nL/min using a PEEK microtight splitting tee (Upchurch Scientific, Oak Harbor, WA), and then delivered to the autosampler using an FSC transfer line.
• the LC pump and autosampler were each controlled using their internal user programs. Samples were inserted into plastic autosampler vials, sealed, and injected using a 5 ⁇ L sample loop.
• Extracted peptides from in-gel digests were separated by the microelectrospray HPLC system using a 50 minute gradient of 0-50% solvent B (A: 0.1 M HOAc, B: 90% MeCN/0.1 M HOAc).
• Peptide analyses were done on a Finnigan LCQ ion trap mass spectrometer (ThermoQuest, San Jose, CA) operating at a spray voltage of 1.5 kV, and using a heated capillary temperature of 150 0 C.
• Data were acquired in automated MS/MS mode using the data acquisition software provided with the instrument. The acquisition method included 1 MS scan (375-1200 m/z) followed by MS/MS scans of the top 3 most abundant ions in the MS scan.
• the ORF 2086 gene was amplified by PCR from a clinical isolate of a serogroup B Neisseria meningitidis strain designated 8529.
• the serogroup, serotype and serosubtype of this strain is shown in parentheses; 8529 (B: 15, P1 :7b,3).
• This meningococcal strain was received from The RIVM, Bilthoven, The Netherlands.
• ORF 2086 A visual inspection of ORF 2086 indicated that this gene had a potential lipoprotein signal sequence. Additional analysis using a proprietary Hidden Markov Model Lipoprotein algorithm confirmed that ORF 2086 contains a lipoprotein signal sequence.
• oligonucleotide primers were designed to amplify the full length gene with the lipoprotein signal sequence intact and were based on an analysis of the Sanger sequence for N. meningitidis A ORF 2086.
• the 2086 gene was amplified by polymerase chain reaction (PCR) [ABI 2400 thermal cycler, Applied Biosystems, Foster City, CA] from N. meningitidis strain 8529.
• the correct size amplified product was ligated and cloned into pCR2.1-TOPO (Invitrogen).
• the plasmid DNA was restriction digested with Ndel and BamHI, gel purified and ligated into pET-27b(+) vector (Novagen).
• Oligonucleotide primers described herein were synthesized on a PerSeptive Biosystems oligonucleotide synthesizer, Applied Biosystems, Foster City CA, using ⁇ - Cyanoethylphosphoramidite chemistry, Applied Biosystems, Foster City CA.
• plasmid pPX7340 was transformed/transfected or infected into BLR(DE3) pLysS host cells (Life Sciences).
• One transformant was selected and inoculated into 50 mL of Terrific Broth containing 2% glucose, kanamycin (30 ⁇ g/mL), chloramphenicol (30 ⁇ g/mL), and tetracycline (12 ⁇ g/mL).
• the OD600 for the overnight culture was 6.0.
• the overnight culture was diluted out in 1 liter of Terrific Broth with 1% glycerol and the same antibiotics.
• the starting OD600 was 0.4. After 2 hours the OD600 was 1.6 and a pre-induced sample was taken.
• the rl_P2086 was solubilized from E. coli following differential detergent extraction. Unlike the P2086 in its native environment, the rl_P2086 was not significantly solubilized by Triton X-100 or Zwittergent 3-12. The bulk of the rl_P2086 was solubilized with sarcosyl, indicating that it interacts with the outer membrane components of E. coli differently than it does in N. meningitidis. Once solubilized the rl_P2086 was purified similarly to the native protein in that many of the contaminating E. coli proteins could be removed by adsorbtion to an anion exchange resin at pH 8.
• the rl_P2086 Despite being greater than one half a pH unit above its theoretical pi, the rl_P2086 remained unadsorbed at pH 8. Further purification was achieved by adsorbtion of the rl_P2086 to a cation exchange resin at pH 4.5.
• the homogeneity of the rl_P2086 is shown in FIG. 2 following SDS-PAGE.
• the mass of rLP2086 was determined by MALDI-TOF mass spectral analysis to be 27,836. This mass differs from the theoretical mass of 27,100 by 736, which approximates the mass of the N-terminal lipid modification common to bacterial lipoproteins. Both native and rl_P2086 appear to be outer membrane lipoproteins. Attempts with N-terminal sequencing were blocked and this is consistent with the terminal modification.
• Frozen pellets of BLR DE3 pLysS cells expressing P2086 were resuspended in 1OmM HEPES-NaOH/1 mM EDTA/1 ⁇ g/mL Pefabloc SC protease inhibitor (Roche) pH 7.4 (HEP) at 2OmUg wet cell weight and lysed by microfluidizer (Microfluidics Corporation Model 110Y). The cell lysate was centrifuged at 150,000 x g for one hour. The pellet was washed twice with HEP and centrifuged twice, and the resulting membrane pellet was frozen overnight.
• the pellet was solubilized with 1OmM HEPES-NaOH/1mM MgCI2/1%TX-100 pH 7.4 for 30 minutes, followed by centrifugation at 150,000 x g for 30 minutes. This was repeated three times.
• the membrane pellet was washed as above twice with 5OmM Tris-HCI/5mM EDTA/1% Zwittergent 3-12 pH 8, followed by two washes each of 5OmM Tris-HCI/5mM EDTA/1% Zwittergent 3-14 pH 8 and 5OmM Tris-HCI/5mM EDTA/1% Zwittergent 3-14/ 0.5M NaCI pH 8.
• the rLP2086 was then solubilized with 5OmM Tris-HCI/5mM EDTA/ 1% sarcosyl pH 8. This sarcosyl extract was adjusted to 1% Zwittergent 3-14 (Z3-14) and dialyzed twice against a 30 fold excess of 5OmM Tris-HCI/5mM EDTA/1% Z3-14. The dialyzed rl_P2086 extract was precipitated with 90% ethanol to remove remaining sarcosyl, and solubilized with 5OmM Tris-HCI/5mM EDTA/ 1% Z3-14 pH 8 (TEZ).
• rl_P2086 was eluted with a 0-0.3M NaCI gradient and analyzed by SDS-PAGE (Coomassie stain). The rl_P2086 pool was determined to be 84% pure by laser densitometry.
• antisera to purified rl_P2086 from the Subfamily B strain 8529 demonstrated surface reactivity to all ten 2086 Subfamily B strains tested by whole cell ELISA. Bactericidal activity was detected against nine of ten 2086 Subfamily B strains expressing heterologous serosubtype antigens, PorAs. These strains are representative of strains causing serogroup B meningococcal disease throughout western Europe, the Americas, Australia, and New Zealand.
• the 2086 Subfamily A strains listed in Table VII were also tested for surface reactivity by whole cell ELISA. Two out of three of these strains appeared to have a very low level of reactivity, indicating that some 2086 Subfamily A strains may not be cross-reactive with antibodies raised to rLP2086 Subfamily B.
• the PCR amplification procedure used to identify the 2086 Subfamily B gene from strain 8529 was also performed on strains 870446, NMB and 6557. No 2086 Subfamily B PCR amplified product was detected.
• Vaccines were formulated as described previously in Example 1. However, a 10 ⁇ g dose was used.
• N. meningitidis whole cell suspensions were diluted to an optical density of 0.1 at 620nm in sterile 0.01 M phosphate, 0.137M NaCI, 0.002M KCI (PBS). From this suspension, 0.1 mL were added to each well of Nunc Bac T 96 well plates (Cat# 2-69620). Cells were dried on the plates at room temperature for three days, then were covered, inverted and stored at 4 0 C.
• Goat-anti- mouse IgG AP (Southern Biotech) was diluted at 1 :1500 in PBS/0.05% Tween-20, 0.1 ml_ was added to each well, and plates were incubated at 37 0 C for two hours. Plates were washed (as above).
• Substrate solution was prepared by diluting p-nitrophenyl phosphate (Sigma) in 1M diethanolamine/0.5mM MgCI 2 to 1mg/ml_. Substrate was added to the plate at 0.1 mL per well and incubated at room temperature for one hour. The reaction was stopped with 50 ⁇ L /well of 3N NaOH and plates were read at 405nm with 690nm reference.
• the N-terminal (5') primers were designed to be homologous to the mature region of the 2086 gene (starting at the serine residue at amino acid position 3 just downstream of the cysteine).
• the restriction site BamHI (GGATTC) was incorporated into the 5' end of each N- terminal primer and resulted in the insertion of a glycine residue in the mature protein at amino acid position 2.
• the C-terminal (3') primers were designed to be homologous to the C-terminal end of the 2086 gene and included the Stop codon as well as an Sphl site for cloning purposes.
• the amplified fragment from each N. meningitidis B strain was cloned into an intermediate vector and screened by sequence analysis.
• Plasmid DNA from correct clones was digested with BamHI and Sphl restriction enzymes (New England Biolabs, (NEB)).
• a vector designated pLP339 (supplied by applicants' assignee) was chosen as the expression vector. This vector utilizes the pBAD18-Cm backbone (Beckwith et a/., 1995) and contains the P4 lipoprotein signal sequence and P4 gene of nontypable Haemophilus influenzae (Green et al., 1991).
• the pLP339 vector was partially digested with the restriction enzyme BamHI and then subjected to Sphl digestion.
• the amplified 2086 fragments (BamHI/Sphl) were each ligated separately into the pLP339 vector (partial BamHI/Sphl).
• This cloning strategy places the mature 2086 gene behind the P4 lipoprotein signal sequence.
• the BamHI site remains in the cloning junction between the P4 signal sequence and the 2086 gene (See the plasmid construct shown in FIG. 7).
• each amplified fragment was cloned into a modified pBAD18-Cm vector containing the P4 leader sequence. Fermentation was performed on recombinant E. coli BLR pPX7343 which expresses rP4LP2086 (recombinant P4 lipidated 2086) to try to increase the cell density by adding additional glucose.
• the fermentor was filled with 10L complete M9 Minimal medium, according to Sambrook, supplemented with 1 % glucose.
• the initial concentration of glucose in the fermentor was 45g/L.
• the fermentor was inoculated to initial OD of -0.25.
• additional 20g/L glucose was added.
• the culture was induced with 1 % arabinose at glucose depletion at OD 63.4.
• the fermentation continued until 3 hours after induction.
• protein yield is -0.35 g/L, and 7% total cellular protein.
• a total of 895 grams of wet cell paste was harvested from ⁇ 10 L of culture.
• Oligonucleotide primers described herein were synthesized on a PerSeptive Biosystems oligonucleotide synthesizer, Applied Biosystems, Foster City CA, using D- Cyanoethylphosphoramidite chemistry, Applied Biosystems, Foster City CA.
• the primers used for PCR amplification of the ORF 2086 gene families are listed in Table IV, which shows non-limiting examples of primers of the present invention.
• the 2086 gene from various stains can be amplified with the primers as described in PCT/US02/32369 (published as WO 03/063766 on August 7, 2003) and PCT/US04/11901 (published as WO 04/094596 on Nov. 4, 2004) which are incorporated herein by reference.
• primers include, a synthetic BgIII restriction site in each primer, a synthetic Ndel restriction site in compound numbers 6406 and 6474 and termination codons in all three reading frames are present in compound numbers 5135 and 6605.
• Primer numbers 6406 and 6474 amplify the 2086 gene with an ATG (Met) fused to the second amino terminal codon (ACG) representing a single amino acid substitution (replaces TGC Cys) of the mature 2086 polypeptide.
• the PCR cloning vector was TOPO-PCR2.1 , Invitrogen, Valencia, CA.
• the vector used to express non-lipidated 2086 protein was pET9a from Novagen, Madison, Wl.
• the E.coli cloning strain was Top10, Invitrogen, Carlsbad, CA.
• the E. coli expression strain was BLR(DE3)pLysS, Novagen, Madison, Wl.
• the culture media for cloning purposes was Terrific Broth liquid or agar, according to Sambrook et a/., with 1 % sterile glucose substituted for glycerol, and the appropriate antibiotic (ampicillin or kanamycin).
• Plasmid purification was with Qiagen Spin Miniprep Kit (Valencia, CA). Preparation of the production strain or cell line for non-lipidated 2086 expression:
• the 2086 gene was amplified by polymerase chain reaction (PCR) [AmpliTaq and ABI 2400 thermal cycler, Applied Biosystems, Foster City, CA] from chromosomal DNA derived from meningococcal strain 8529.
• PCR polymerase chain reaction
• the PCR amplification of the 2086 gene utilized two oligonucleotide primers in each reaction identified by compound numbers 6474 and 5135.
• the amplified 2086 PCR product was cloned directly into the TOPO-PCR2.1 cloning vector and selected on Terrific Broth agar supplemented with 100 ⁇ g/ml ampicillin and 20 ⁇ g/ml X-GaI. White colonies were selected and grown.
• Plasmid DNA was prepared using a Qiagen miniprep kit and the plasmids were screened for the PCR fragment insert. PCR insert plasmids were subjected to DNA sequencing (Big Dye chemistry on an ABI377 sequencer, Applied Biosystems, Foster City, CA).
• Plasmids exhibiting the correct DNA sequence were digested with BgIII restriction enzyme and the BgIII fragment was gel purified using a GeneClean Il purification kit (Bio101 , Carlsbad, CA). The purified BgIII fragment was cloned into the BamHI site of the expression vector pET9a.
• the pET9a/2086 clones were selected on Terrific Broth plates supplemented with 30 ⁇ g/ml kanamycin. Kanamycin resistant clones were grown and miniprep plasmid DNA was prepared. The plasmids were screened for the appropriate orientation of the 2086 gene in the BamHI site.
• Correctly oriented plasmids represent a fusion of the T7-antigen to the amino terminus of 2086 gene (rP2086T7).
• rP2086T7 gene fusions were transformed into BLR(DE3)pLysS, selected on Terrific Broth/Kan plates, grown in Terrific Broth and induced to express the rP2086T7 fusion protein with 1 mM IPTG (isopropyl ⁇ -D-thiogalactopyranoside). The rP2086T7 fusion protein expressed at high levels.
• fusion plasmids were then subjected to a Ndel restriction digest, which deletes the T7-antigen and links the mature 2086 gene directly to the ATG start provided by the vector.
• Ndel deleted plasmids were transformed into Top10 cells and selected on Terrific Broth/Kan plates.
• Candidate clones were grown and miniprep plasmid DNA was prepared.
• the plasmid DNA was subjected to DNA sequencing to confirm the deletion and the integrity of the 2086 gene sequence.
• These plasmids are represented by the plasmid map designated pPX7328 (FIG. 6).
• Plasmids representing the correct DNA sequence were transformed into BLR(DE3)pLysS, selected on Terrific Broth/Kan plates, grown in Terrific Broth and induced to express the 2086 protein with IPTG.
• the pET9a vector failed to express the mature 2086 protein, in strain BLR(DE3)pLysS, when the T7-Tag was removed. Production of non-lipidated 2086 protein:
• Purified plasmid DNA was used to transform the expression strain BLR(DE3)pLysS.
• BLR(DE3)pLysS cells carrying the plasmids are resistant to kanamycin and can be induced to express high levels of PorA protein by the addition of 1 mM IPTG.
• the rP2086T7 fusion protein can be expressed as insoluble inclusion bodies in the E.coli cell line BLR(DE3)pLysS at ⁇ 40% of total protein. This purified fusion protein was used to immunize mice and generated significant levels of bactericidal antibodies against a heterologous meningococcal strain. (See Table V)
• PCR primer mutagenesis was performed on the 5' end of the 2086 gene. Expression studies are under way to determine if the T7-Tag can be removed while exhibiting the high expression levels of mature rP2086T7.
• E. coli BLR(DE3)pLysS cells expressing non-lipidated rP2086T7 were lysed by microfluidizer in 1OmM Hepes-NaOH/5mM EDTA/1mM Pefabloc SC pH 7.4. The cell lysate was then centrifuged at 18,000xg for 30 minutes. The inclusion body pellet was washed three times with 5OmM Tris-HCI/5mM EDTA/1% TritonX-100 pH 8 followed by centrifugation each time at 24,000xg for 30 min.
• the inclusion body pellet was then washed twice with 5OmM Tris-HCI/5mM EDTA/1% Zwittergent 3-14 pH 8 followed by centrifugation each time at 24,000xg for 15min.
• the inclusion body pellet was then solubilized with 5OmM Tris- HCI/5mM EDTA/4M Urea pH 8 for two hours followed by centrifugation to remove insoluble material.
• the supernatant (solubilized rP2086T7) was split into four equal samples.
• This purified fusion protein was used to immunize mice and generated significant levels of bactericidal antibodies against a heterologous meningococcal strain. (See Table V below):
• the N-terminal region of the 2086 gene from strain CDC-1573 contains a repeated segment not present in the 2086 gene from strains 8529 and 2996 (see FIG. 8). It appears that this repeated segment is responsible for increased levels of recombinant 2086 protein expression from two E.coli based expression systems (pET and pBAD). The recombinant protein expression level from the CDC-1573 2086 gene was significantly better in the pET and pBAD expression systems as compared to the recombinant expression levels from the 2086 gene with strains 8529 and 2996 using the same systems. The N-terminal region of the 2086 gene from all three strains is relatively homologous, except for this repeated segment.
• Chromosomal DNA from strains 8529 and 2996 was purified and used as a template for PCR amplification of the chimeric 2086 gene.
• PCR primers with the compound numbers 6721 and 5135 were used to amplify the chimeric 2086 gene from strain 8529 and PCR primers with the compound numbers 6721 and 6605 were used to amplify the chimeric 2086 gene from strain 2996.
• the PCR products were cloned directly into the PCR2.1 TOPO vector from Invitrogen and then screened by DNA sequence analysis to identify an intact chimeric 2086 gene.
• That gene was then cleaved from the PCR2.1 vector with BgIII and the BgIII fragment was inserted into the BamHI site of the pET9a plasmid. Plasmid inserts were screened for the appropriate orientation and then subjected to an Ndel digestion. The linear Ndel fragments were self-ligated to achieve the deletion of a small Ndel fragment containing the T7-tag sequence contributed by the pET9a vector. This deletion directly links the T7 promoter to the 5' end of the chimeric 2086 gene. The Ndel deleted plasmid was transformed into E. coli strain BL21 (DE3) and kanamycin resistant colonies were screened for chimeric 2086 protein expression with IPTG induction.
• the 2086 gene from strain 6557 was ⁇ 75% identical at the amino acid level to the other strains sequenced.
• strain 6557 was one of the 30% of strains that had previously tested negative by 2086 PCR screening described above.
• N. meningitidis strains used for PCR amplification studies were selected from the following tables, Table VIA and Table VIB.
• the strains listed in the tables are provided as examples of N. meningitidis strains in addition to those previously disclosed herein, without limitation.
• the strains listed in Table VIA are classified in 2086 protein Subfamily A and the strains listed in Table VIB are classified in 2086 protein Subfamily B.
• the strains listed in each table are grouped by serosubtype.
• strains are available from the following four sources as indicated in the table: MPHL-Manchester Public Health Laboratory, Manchester, UK; RIVM, Bilthoven, The Netherlands; University of Iowa, College of Medicine, Department of Microbiology, Iowa City, IA; and Walter Reed Army Institute of Research, Washington, D.C.
• Table VII shows the cross-reactive and cross protection capacity of the rLP2086 as described above.
• the rLP2086 was processed and analyzed using a variety of techniques including whole cell ELISA (WCE) titers, bactericidal assay (BCA) and Infant Rat (IR) assays to determine the bacterial cell surface reactivity of a polyclonal antibody raised against the 2086 protein.
• WCE whole cell ELISA
• BCA bactericidal assay
• IR Infant Rat
• P2086 is a lipidated outer membrane protein(LP2086).
• rl_P2086-8529 and variants from other meningococcal strains were recombinantly expressed as lipoproteins in E.coli using the H. influenzae P4 signal sequence. These recombinant proteins were isolated from E.coli membranes by differential detergent extraction, purified using ion exchange chromatography, and used to immunize mice. Mouse anti-LP2086 sera were able to facilitate bactericidal activity against several different serosubtype strains of N. meningitidis. Further analysis of the P2086 genes from many N.
• Subfamily A and Subfamily B meningitidis strains showed that these sequences fell into two groups designated Subfamily A and Subfamily B.
• the antisera raised against the Subfamily B proteins were bactericidal against nine strains expressing Subfamily B proteins, and one strain expressing a Subfamily A protein.
• Subfamily A antisera were bactericidal against Subfamily A strains.
• a mixture of one rPorA and one rl_P2086 elicited complementary antibodies extending vaccine coverage beyond that induced by either protein alone.
• rl_P2086 antigens are capable of eliciting bactericidal antibodies against meningococcal strains expressing heterologous PorAs and heterologous P2086 proteins.
• the P2086 family of antigens may be a useful vaccine or immunogenic either alone or in combination with other neisserial antigens.
• a complex mixture of soluble outer membrane proteins (sOMPs) was found to elicit PorA independent bactericidal antibody against strains expressing heterologous PorA proteins.
• a process of differential detergent extraction, isoelectric focusing and ion exchange chromatography followed by mouse immunization was used to follow the immunologically active components.
• Bactericidal Assay See Mountzourous, KT. and Howell, A. P. Detection of Complement-Mediated Antibody-Dependent Bactericidal Activity in a Flourescence-Based Serum Bactericidal Assay for Group B Neisseria meningitidis. J Clin Microbiol. 2000;38:2878-2884.
• ELISA Whole Cell Enzyme Linked lmmonosorbant Assay
• Dilutions of antisera were prepared in PBS, 0.05% Tween-20/Azide and 0.1ml_ was transferred to the coated plates and incubated for two hours at 37°C. Plates were washed three times in wash buffer. Goat-anti-mouse IgG AP (Southern Biotech) was diluted at 1 :1500 in PBS/0.05% Tween-20, 0.1 ml_ was added to each well, and plates were incubated at 37°C for two hours. Plates were washed (as above). Substrate solution was prepared by diluting p-nitrophenyl phosphate (Sigma) in diethanolamine at 1 mg/ml . Substrate was added to the plate at 0.1mL per well and incubated at room temperature for one hour. The reaction was stopped with 50ul/well of 3N NaOH and plates were read at 405nm with 690nm reference.
• sOMPs N. meningitidis membranes were extracted with TX-100, Zwittergent 3-14, and Zwittergent 3-14+0.5M NaCI. The sOMPs referred to above were solubilized in the Zwittergent 3-14/0.5M NaCI extract. The extraction is performed using techniques well known to persons skilled in the art, for example, see U.S. Patent No. 6,355,253 which is hereby incorporated by reference.
• BC 50 Bactericidal titers represented as the reciprocal of the dilution of anti- sera which reduces viable cell count by 50%. Week 0 normal mouse sera had BC 50 titers of ⁇ 25
• Table Xand Table Xl show the purification and characterization summary for recombinant lipidated P2086 (rl_P2086) for both Subfamily A and Subfamily B.
• Table XII shows immunogenicity of a Subfamily B member, rLP2086- 8529, tested against homologous and heterologous strains
• Vaccination Procedure 6-8 week old female Swiss-Webster mice were immunized with 10ug rLP2086-8529+20ug QS-21 at week 0 and week 4. Data analysis was performed on the week 6 exsanguination bleed. [0248] aAmino acid homology of P2086 as compared with rl_P2086-8529
• BC50 titers represented as the reciprocal of the dilution of anti-sera which reduces viable cell count by 50%. Week 0 normal mouse sera had BC50 titers of ⁇ 10.
• Table XIII shows immunogenicity of a Subfamily B member, rl_P2086-2996, tested against homologous and heterologous strains.
• Vaccination Procedure 6-8 week old female Swiss-Webster mice were immunized with 10ug rl_P2086-2996+20ug QS-21 at week 0 and week 4. Data analysis was performed on the week 6 exsanguination bleed.
• Table XIV below shows that antisera to rl_P2086 and rPorA are complimentary when mixed and assayed for bactericidal activity.
• Vaccination Procedure 6-8 week old female Swiss-Webster mice were immunized with either 10ug rl_P2086-8529/20ug QS-21 , or 15ug rPorA/100ug MPL at week 0 and week 4. Data analysis was performed on the week 6 exsanguination bleed.
• BC50 Bactericidal titers represented as the reciprocal of the dilution of antisera which reduces viable cell count by 50%. Week 0 normal mouse sera had BC50 titers of ⁇ 10.
• Table XV shows that mixtures of rLP2086 Subfamilies and two rPorAs elicit bactericidal antibody in mice.
• Vaccination Procedure 6-8 week old female Swiss-Webster mice were immunized with 10ug of each protein + 20ug QS-21 at week 0 and week 4. Data analysis was performed on the week 6 exsanguination bleed.
• BC50 Bactericidal
• Anti- rl_P2086 antisera is bactericidal against 13/16 test strains. Eleven strains expressing different serosubtypes are killed by anti-P2086 sera. Bactericidal activity of anti-rl_P2086 sera is complimentary to anti-rPorA sera. Mixtures of P2086 and PorA elicit complimentary bactericidal antibodies in mice. Differential detergent extraction, purification and immunization in conjunction with a functional antibody assay against many strains can be used to identify new vaccine candidates. P2086 has been identified as a vaccine candidate that elicits bactericidal antibody against strains heterologous in both P2086 and rPorA. Thus, the 2086 family of proteins may be a useful vaccine either alone or in combination with other neisserial antigens.
• Meningococcal strains of varying serogroups, were screened by PCR for the presence of the ORF 2086 gene. Ultimately, over one hundred meningococcal strains were screened.
• 2086 genes were recombinantly expressed as an rl_P2086 lipoprotein in a pBAD arabinose inducible promoter system or as an rP2086 non-lipidated protein in an IPTG inducible pET system. These recombinant proteins were expressed in E.coli B. The purified recombinant protein was used to immunize mice and the mouse antisera was assayed for its serum IgG titers and its bactericidal activity against a variety of heterologous meningococcal strains.
• ORF 2086 was amplified by PCR from one of the following: whole meningococcal cells, purified chromosomal DNA or plasmid DNA templates.
• ORF 2086 genes were cloned into the vector pLP339, which fuses the Haemophilus P4 leader sequence to the 5' end of the ORF 2086 genes.
• E.coli strain BLR was used as the host strain for recombinant expression of the lipidated form of rP2086 from the pBAD/ORF 2086 clones.
• the pBAD arabinose inducible promoter drives the expression the P4 signal/ORF 2086 fusion protein to express a lipidated form of rP2086.
• P2086 genes lacking a signal sequence were cloned into a pET9a vector behind the highly active T7 phage promoter.
• E.coli strain BL21(DE3) was used as the host strain for recombinant expression of a non-lipidated form of ORF 2086 from the pET9a/ORF 2086 clones.
• the DE3 lysogen in E.coli strain BL21 can be induced to express the T7 RNA polymerase under the control of the lacUV5 promoter by addition of IPTG. See, WCE; FEMS Micro. Lett., 48 (1987) 367-371 and BCA; J. CHn. Microbiol., 38 (2000) 2878-2884.
• ORF2086 The gene, ORF2086, was cloned and sequenced from different N. meningitidis strains. The nucleotide sequences were aligned (DNAStar MegAlign) and used to generate a phylogenetic tree. This tree reveals two distinct subfamilies of the ORF 2086 gene nucleotide sequence. The two subfamilies of genes are similar at their 5' ends, but contain considerable variation near their 3' ends. Although there appears to be significant variability, certain key regions of the gene are highly homologous among the different strains. Without intending to be bound by theory, these conserved regions may provide functional continuity for the protein and may be indicative of cross-protective epitopes to be exploited as vaccine targets.
• the 2086 gene was cloned from several serogroup B meningococcal strains and expressed with and without the lipidation signal sequence.
• the non-lipidated form fused to the T7-Tag expressed at the highest level.
• the T7-Tag sequence may provide stability to the mRNA and significantly enhances the level of polypeptide translated.
• This fusion protein appears to deposit in inclusion bodies and can be purified and refolded readily with known protocols.
• the lipidated and non-lipidated forms of P2086 are expressed at approximately 5 to 8% of total cellular protein, with the exception of the T7-Tag fusions, which express rP2086 as approximately 50% of total protein.
• the non-lipidated form of the protein appears to be soluble and localized in the cytoplasm.
• the lipidated form of the protein appears to be associated with the membrane fractions and is solubilized with detergent.
• the protein in its native lipidated form may have superior tertiary structure for antigen presentation and/or the attached lipid may act as an adjuvant stimulating a greater immunogenic response.
• All N. meningitidis B strains tested appear to have one 2086-like gene. At least two families of the 2086 gene are represented. 2086 homologs have been identified by PCR screening in the following:
• the resulting antisera is bactericidal.
• rLP2086 consistently elicits a greater immune response than rP2086.
• rl_P2086 also exhibits enhanced bactericidal activity against both homologous and heterologous meningococcal strains.
• Cell lysates were prepared with cells from plate cultures resuspended in SDS sample buffer and heated at 98°C for four minutes. Samples were loaded at ⁇ 30-50ug total protein per well on 10-20% pre-cast gels (ICN) and run at 175V. The gels were transferred to a nitrocellulose membrane, which was then blocked for 30min. with 5% powdered milk in Tris-buffered saline (Blotto). The primary antibody used was a pool of polyclonal antisera raised against individual rl_P2086 variants in mice.
• a Western Blot shows the reactivity of rLP2086 mouse antisera to P2086 Subfamily A and B whole cell lysates.
• the antisera used were raised against rl_P2086-2996, -870446 and -250771 with rl_P2086-250771 diluted at 1/500 in Blotto and the others diluted at 1/1000 in Blotto.
• the antisera used were raised against rl_P2086-8529 (diluted 1/1000 in Blotto), -CDC1573.
• Protein F a fibronectin-binding protein, is an adhesion of the group A streptococcus Streptococcus pyogenes. Proc Natl Acad Sci., USA. 89:6172-76.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Immunology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Microbiology (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (3)

Family

ID=39563116

Family Applications (1)

Country Status (12)

Cited By (27)

Families Citing this family (11)

Family Cites Families (164)

• 2007
  • 2007-12-20 AR ARP070105809A patent/AR064642A1/es unknown
  • 2007-12-21 EP EP07853461A patent/EP2094294A2/en not_active Withdrawn
  • 2007-12-21 CL CL200703771A patent/CL2007003771A1/es unknown
  • 2007-12-21 JP JP2009542957A patent/JP2010512792A/ja active Pending
  • 2007-12-21 BR BRPI0721003A patent/BRPI0721003B8/pt active IP Right Grant
  • 2007-12-21 CA CA2673515A patent/CA2673515C/en active Active
  • 2007-12-21 CN CN200780047494A patent/CN101631858A/zh active Pending
  • 2007-12-21 US US12/004,869 patent/US8574597B2/en active Active
  • 2007-12-21 AU AU2007338690A patent/AU2007338690B2/en active Active
  • 2007-12-21 TW TW096149621A patent/TW200844226A/zh unknown
  • 2007-12-21 WO PCT/US2007/026238 patent/WO2008079372A2/en not_active Ceased
  • 2007-12-21 MX MX2009006760A patent/MX2009006760A/es active IP Right Grant

Also Published As

Similar Documents

Legal Events